Main uses and applicable groups of Inavolisib

Inavolisib is an oral small molecule selective PI3Kα inhibitor that mainly targets the PIK3CA mutation pathway. This mutation is common in hormone receptor-positive, HER2-negative breast cancer and is an important driver of abnormal tumor cell proliferation. By inhibitingPI3Kα, inalisate can block signaling pathways, reduce the proliferation and survival of tumor cells, and delay disease progression. Clinical studies have shown that when inaliset is used in combination with palbociclib and fulvestrant, it can significantly improve the efficacy of patients with endocrine-resistant breast cancer and provide a new treatment option for patients with refractory HR-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer.

The applicable population is mainly adult female patients who relapse after completing adjuvant endocrine therapy or during treatment, and whose tumors are PIK3CA mutation-positive as tested by an FDA-approved test Such patients are often resistant to conventional endocrine therapy. By combining inaliset, palbociclib, and fulvestrant, treatment can be more precisely targeted at the molecular characteristics of the tumor, thereby prolonging progression-free survival and improving quality of life. Overseas studies have shown that combination therapy can significantly inhibit tumor growth while maintaining controllable safety, providing a new feasible strategy for patients with endocrine-resistant HR-positive breast cancer.

The efficacy of inalised depends on the results of molecular testing, so PIK3CA mutation screening should be performed before starting treatment.PIK3CA mutation screening should be performed. In patients without this mutation, use of inaliset may not confer significant benefit. In addition, patients should undergo regular tumor evaluation and hematology tests during treatment to ensure drug efficacy and safety.

In short, inaliside provides a new option for precise targeted therapy for patients with endocrine-resistant, PIK3CA mutated breast cancer, and is especially suitable for use in combination regimens to improve clinical benefit and delay disease progression.

Reference materials:https://www.itovebi-hcp.com/